In this multicenter , double-blind , double-dummy , randomized phase @ study , we assigned patients who had ACE-inhibitor-induced angioedema of the upper aerodigestive tract to treatment with @ mg of subcutaneous icatibant , a selective bradykinin B@ receptor antagonist , or to the current off-label standard therapy consisting of intravenous prednisolone ( @ mg ) plus clemastine ( @ mg ) .